{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T22:09:49Z","timestamp":1778018989648,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2021-I2M-1-028"],"award-info":[{"award-number":["2021-I2M-1-028"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bioorg.2025.109064","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T15:13:15Z","timestamp":1759504395000},"page":"109064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Design, synthesis and evaluation of novel UDCA-tetrahydropyrazine triazole hybrids for the treatment of pulmonary fibrosis"],"prefix":"10.1016","volume":"166","author":[{"given":"Yue","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuoyu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiawei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.109064_bb0005","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1056\/NEJMra1300575","article-title":"Fibrosis--a common pathway to organ injury and failure","volume":"372","author":"Rockey","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.109064_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00855","article-title":"Drugs and targets in fibrosis","volume":"8","author":"Li","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109064_bb0015","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","article-title":"Clinical course and prediction of survival in idiopathic pulmonary fibrosis","volume":"183","author":"Ley","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.bioorg.2025.109064_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28093674","article-title":"Recent advances (2015-2020) in drug discovery for attenuation of pulmonary fibrosis and COPD","volume":"28","author":"Dorababu","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109064_bb0025","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.109064_bb0030","doi-asserted-by":"crossref","first-page":"5961","DOI":"10.1038\/s41598-018-24303-4","article-title":"Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"8","author":"Biondini","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.109064_bb0035","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s12325-019-00906-9","article-title":"Long-term effects and adverse events of Nintedanib therapy in idiopathic pulmonary fibrosis patients with functionally advanced disease","volume":"36","author":"Barczi","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.bioorg.2025.109064_bb0040","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12931-021-01857-y","article-title":"Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study","volume":"22","author":"Marijic","year":"2021","journal-title":"Respir. Res."},{"key":"10.1016\/j.bioorg.2025.109064_bb0045","doi-asserted-by":"crossref","first-page":"25822","DOI":"10.1074\/jbc.M605142200","article-title":"Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid","volume":"281","author":"Tanaka","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.109064_bb0050","doi-asserted-by":"crossref","first-page":"39436","DOI":"10.1074\/jbc.M205623200","article-title":"Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase","volume":"277","author":"Tokumura","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.109064_bb0055","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1021\/acschemneuro.1c00641","article-title":"Novel Thienopyrimidine-based PET tracers for P2Y(12) receptor imaging in the brain","volume":"12","author":"van der Wildt","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bioorg.2025.109064_bb0060","article-title":"Development and validation for quantification of 7-nitroso impurity in sitagliptin by ultraperformance liquid chromatography with triple quadrupole mass spectrometry","volume":"27","author":"Chittireddy","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109064_bb0065","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10593-023-03213-y","article-title":"Focused small molecule library of 5,6,7,8-tetrahydro[1,2,4]triazolo-[4,3-a]pyrazines: a brick for the house of medicinal chemistry","volume":"59","author":"Borysov","year":"2023","journal-title":"Chem. Heterocycl. Compd."},{"key":"10.1016\/j.bioorg.2025.109064_bb0070","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40265-016-0686-9","article-title":"Sitagliptin: a review in type 2 diabetes","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2025.109064_bb0075","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1021\/acs.jmedchem.4c02719","article-title":"Discovery of novel 4,5,6,7-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one derivatives as orally efficacious ATX allosteric inhibitors for the treatment of pulmonary fibrosis","volume":"68","author":"Ma","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109064_bb0080","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/13543776.2021.1867106","article-title":"An updated patent review of autotaxin inhibitors (2017-present)","volume":"31","author":"Tan","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2025.109064_bb0085","doi-asserted-by":"crossref","first-page":"7476","DOI":"10.1021\/acs.jmedchem.4c03173","article-title":"Development of tricyclic 4,5-dihydro-3H-pyrrolo[2,3-c]quinolin-4-ones as potent Autotaxin inhibitors for pulmonary fibrosis treatment in vivo","volume":"68","author":"Ma","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109064_bb0090","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1021\/acs.jmedchem.8b00232","article-title":"Hydroxamic acids constitute a novel class of Autotaxin inhibitors that exhibit in vivo efficacy in a pulmonary fibrosis model","volume":"61","author":"Nikolaou","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109064_bb0095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/19490976.2015.1127483","article-title":"Consequences of bile salt biotransformations by intestinal bacteria","volume":"7","author":"Ridlon","year":"2016","journal-title":"Gut Microbes"},{"key":"10.1016\/j.bioorg.2025.109064_bb0100","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0168-8278(01)00092-7","article-title":"Ursodeoxycholic acid \u2018mechanisms of action and clinical use in hepatobiliary disorders\u2019","volume":"35","author":"Lazaridis","year":"2001","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bioorg.2025.109064_bb0105","doi-asserted-by":"crossref","DOI":"10.1128\/AEM.02766-16","article-title":"Ursodeoxycholic acid and its taurine- or Glycine-conjugated species reduce colitogenic dysbiosis and equally suppress experimental colitis in mice","volume":"83","author":"Van den Bossche","year":"2017","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.bioorg.2025.109064_bb0110","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bbi.2021.09.021","article-title":"From dried bear bile to molecular investigation: a systematic review of the effect of bile acids on cell apoptosis, oxidative stress and inflammation in the brain, across pre-clinical models of neurological, neurodegenerative and neuropsychiatric disorders","volume":"99","author":"Huang","year":"2022","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bioorg.2025.109064_bb0115","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1021\/acs.jmedchem.6b01743","article-title":"Rational Design of Autotaxin Inhibitors by structural evolution of endogenous modulators","volume":"60","author":"Keune","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109064_bb0120","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216333","article-title":"A type IV Autotaxin inhibitor ameliorates acute liver injury and nonalcoholic steatohepatitis","volume":"14","author":"Booijink","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bioorg.2025.109064_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116029","article-title":"Design, synthesis and evaluation of novel UDCA-aminopyrimidine hybrids as ATX inhibitors for the treatment of hepatic and pulmonary fibrosis","volume":"264","author":"Hu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109064_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24044004","article-title":"Fibrosis: types, effects, markers, mechanisms for disease progression, and its relation with oxidative stress, immunity, and inflammation","volume":"24","author":"Antar","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109064_bb0135","first-page":"47","article-title":"Progress in drug delivery system for fibrosis therapy, Asian","volume":"16","author":"Xing","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2025.109064_bb0140","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","article-title":"Fibrosis: from mechanisms to medicines","volume":"587","author":"Henderson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.109064_bb0145","article-title":"Design and synthesis of Matrine derivatives as novel anti-pulmonary fibrotic agents via repression of the TGF\u03b2\/Smad pathway","volume":"24","author":"Li","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109064_bb0150","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/path.1427","article-title":"The myofibroblast in wound healing and fibrocontractive diseases","volume":"200","author":"Gabbiani","year":"2003","journal-title":"J. Pathol."},{"key":"10.1016\/j.bioorg.2025.109064_bb0155","first-page":"162","article-title":"Chemical components in cultivated cordyceps sinensis and their effects on fibrosis","volume":"16","author":"Dong","year":"2024","journal-title":"Chin. Herb. Med."},{"key":"10.1016\/j.bioorg.2025.109064_bb0160","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/08977194.2011.595714","article-title":"TGF-\u03b2 signaling in fibrosis","volume":"29","author":"Biernacka","year":"2011","journal-title":"Growth Factors"},{"key":"10.1016\/j.bioorg.2025.109064_bb0165","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature02006","article-title":"Smad-dependent and Smad-independent pathways in TGF-beta family signalling","volume":"425","author":"Derynck","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.109064_bb0170","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12943-022-01569-x","article-title":"Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy","volume":"21","author":"Peng","year":"2022","journal-title":"Mol. Cancer"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825009447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825009447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:59:16Z","timestamp":1777463956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825009447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":34,"alternative-id":["S0045206825009447"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109064","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and evaluation of novel UDCA-tetrahydropyrazine triazole hybrids for the treatment of pulmonary fibrosis","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109064"}}